JP2015227351A5 - - Google Patents

Download PDF

Info

Publication number
JP2015227351A5
JP2015227351A5 JP2015140309A JP2015140309A JP2015227351A5 JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5 JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antimetabolite
cancer
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015140309A
Other languages
English (en)
Japanese (ja)
Other versions
JP6352863B2 (ja
JP2015227351A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015227351A publication Critical patent/JP2015227351A/ja
Publication of JP2015227351A5 publication Critical patent/JP2015227351A5/ja
Application granted granted Critical
Publication of JP6352863B2 publication Critical patent/JP6352863B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2015140309A 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法 Expired - Fee Related JP6352863B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55357804P 2004-03-15 2004-03-15
US60/553,578 2004-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014091125A Division JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016248041A Division JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法

Publications (3)

Publication Number Publication Date
JP2015227351A JP2015227351A (ja) 2015-12-17
JP2015227351A5 true JP2015227351A5 (enExample) 2016-02-04
JP6352863B2 JP6352863B2 (ja) 2018-07-04

Family

ID=34993432

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2007503972A Expired - Fee Related JP5096913B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法
JP2014091125A Expired - Fee Related JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法
JP2015140309A Expired - Fee Related JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2007503972A Expired - Fee Related JP5096913B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法
JP2014091125A Expired - Fee Related JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Country Status (23)

Country Link
US (12) US7989468B2 (enExample)
EP (4) EP3053579A1 (enExample)
JP (9) JP5096913B2 (enExample)
KR (1) KR101169825B1 (enExample)
CN (5) CN101703508A (enExample)
AT (2) ATE493982T1 (enExample)
AU (3) AU2005222622B2 (enExample)
BR (1) BRPI0508700A (enExample)
CA (3) CA2954578A1 (enExample)
CY (2) CY1109741T1 (enExample)
DE (2) DE602005025738D1 (enExample)
DK (3) DK2295056T5 (enExample)
ES (3) ES2358267T3 (enExample)
HU (1) HUE027266T2 (enExample)
IL (2) IL177946A (enExample)
MX (2) MXPA06010382A (enExample)
NO (3) NO338058B1 (enExample)
NZ (2) NZ549557A (enExample)
PL (3) PL2295056T3 (enExample)
PT (2) PT1725233E (enExample)
SI (2) SI1725233T1 (enExample)
WO (2) WO2005089756A1 (enExample)
ZA (1) ZA200607248B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
WO2006034113A2 (en) 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080041298A (ko) * 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
CA2845095A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
BRPI0713637A2 (pt) 2006-06-12 2012-10-23 Sunesis Pharmaceuticals Inc composição, composto, e , método para o tratamento de cáncer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
WO2009049030A1 (en) * 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
AU2014277779B2 (en) * 2007-10-22 2016-05-19 Sunesis Pharmaceuticals, Inc. METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
WO2010078294A1 (en) 2008-12-31 2010-07-08 Sunesis Pharmaceutical, Inc. Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG10201400258SA (en) 2009-02-27 2014-05-29 Sunesis Pharmaceuticals Inc Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
CN104244697B (zh) 2012-02-27 2018-04-27 阿吉齐科技公司 土壤条件的监测与控制
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
PT2970218T (pt) 2013-03-12 2019-03-01 Vertex Pharma Inibidores de adn-pk
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
US20160136173A1 (en) * 2013-07-02 2016-05-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
WO2025033367A1 (ja) * 2023-08-04 2025-02-13 湧永製薬株式会社 抗腫瘍剤併用療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US216316A (en) * 1879-06-10 Improvement in latches
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
RO117793B1 (ro) * 1994-06-14 2002-07-30 Dainippon Pharmaceutical Co Derivati de acid piridoncarboxilic si compozitie farmaceutica care ii contine
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
DE69813194T2 (de) * 1997-01-13 2004-02-05 Kudos Pharmaceuticals Ltd. Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
WO1998055615A1 (en) 1997-06-05 1998-12-10 The University Of Texas Board Or Regents Apaf-1, the ced-4 human homolog, an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2332179C (en) * 1998-06-30 2011-06-28 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
EP1161444A4 (en) * 1999-02-26 2005-11-02 Univ Johns Hopkins A novel inhibitor of programmed cell death
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
JP2004500849A (ja) * 2000-05-20 2004-01-15 キャンサー・リサーチ・テクノロジー・リミテッド 薬剤スクリーニングシステム及びアッセイ
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
WO2002036171A1 (en) * 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
AU2003253593A1 (en) * 2002-04-05 2003-11-03 Richard A. Fishel Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
JP2006523681A (ja) * 2003-03-24 2006-10-19 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン
AU2005222622B2 (en) * 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
KR20080041298A (ko) 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
BRPI0713637A2 (pt) 2006-06-12 2012-10-23 Sunesis Pharmaceuticals Inc composição, composto, e , método para o tratamento de cáncer
WO2008016678A2 (en) 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2214662B1 (en) 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2649997B1 (en) 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
WO2010078294A1 (en) 2008-12-31 2010-07-08 Sunesis Pharmaceutical, Inc. Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG10201400258SA (en) 2009-02-27 2014-05-29 Sunesis Pharmaceuticals Inc Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity
CN101631081B (zh) 2009-08-12 2011-06-08 华为技术有限公司 一种多级交换网
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015227351A5 (enExample)
JP2014148535A5 (enExample)
JP2014040437A5 (enExample)
JP2016508134A5 (enExample)
JP2009545601A5 (enExample)
WO2009075841A3 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2008016702A3 (en) Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
EA201890458A1 (ru) Композиции с усилителями проницаемости для доставки лекарств
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
JP2016539157A5 (enExample)
WO2015184145A8 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
NZ718708A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12012502447A1 (en) Tetrahydrocarboline derivative
PH12014500386A1 (en) Combination treatment for hepatitis c
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
EP4356912A3 (en) High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
JP2009539994A5 (enExample)
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2015502926A5 (enExample)
EP4324824A3 (en) Combination antibacterial composition and short-course antibacterial regimen
WO2016178092A3 (en) C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
JP2011500805A5 (enExample)